V N Nesterova studies how well the medication Revelise (which is a form of alteplase) works for patients who have suffered ischemic strokes. This condition occurs when a blood clot blocks blood flow to the brain, causing brain damage. In their recent research, Nesterova followed the recovery of patients treated with Revelise, primarily looking at older individuals and those with additional health challenges. The goal is to assess not only the effectiveness of this treatment but also its safety and overall impact on patients' quality of life after a stroke.
Key findings
In a study involving 2,202 patients treated with Revelise, 49.9% experienced good outcomes upon discharge from the hospital.
After 90 days of treatment with Revelise, this percentage improved to 66.4%, showing significant recovery from stroke-related disabilities.
The research indicates that Revelise is effective even among older patients and those with other pre-existing health conditions.
Frequently asked questions
Does Dr. Nesterova study ischemic stroke?
Yes, Dr. Nesterova focuses on the treatment and outcomes of ischemic stroke patients.
What treatments has Dr. Nesterova researched?
Dr. Nesterova has researched the use of Revelise, a thrombolytic medication for treating ischemic strokes.
Is Dr. Nesterova's work relevant to older stroke patients?
Yes, their research specifically looks at older patients and shows positive treatment outcomes for this group.
Publications in plain English
[Fortelyzin for acute ischaemic stroke treatment in an extended (4.5 to 24 hours from the onset of symptoms) time window: data from the observational study FORPI registry].
2026
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Shamalov NA, Martynov MY, Gusev EI, Marskaya NA, Khasanova DR +27 more
Plain English This study looked at the use of the drug Fortelyzin to treat patients who had an acute ischemic stroke (AIS) when they received treatment between 4.5 and 24 hours after their symptoms started. Researchers found that 61% of patients treated within the first 4.5 hours had a good recovery, while 65% of those treated later also had a good recovery, showing that treatment is still effective even when started later. The rates of serious complications were similar in both groups, indicating that Fortelyzin is a safe option for stroke patients, regardless of when they receive treatment.
Who this helps: This helps stroke patients who may not get to the hospital within the first few hours of their symptoms.
[Fortelizin in bridging therapy of acute ischemic stroke: data from the observational study FORPI registry].
2026
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Shamalov NA, Martynov MY, Gusev EI, Khasanova DR, Nesterova VN +27 more
Plain English This study looked at how safe and effective a drug called Fortelyzin is for people having an acute ischemic stroke, specifically when used during treatments that involve both thrombolysis and thrombectomy. Out of 1,116 patients, 38% had a good recovery after 90 days, while 29% died in that time. The findings are important because they show that Fortelyzin can be a useful option in treating stroke patients in everyday healthcare settings.
Who this helps: This benefits doctors and patients dealing with acute ischemic strokes.
[Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry].
2025
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Shamalov NA, Martynov MY, Gusev EI, Marskaya NA, Khasanova DR +92 more
Plain English This study looked at how safe and effective the drug Fortelyzin is for treating patients with acute ischemic stroke (AIS). Researchers followed 17,636 patients across 329 centers between March 2021 and October 2024. They found that 61% of patients experienced good outcomes after 90 days, and only 2% had serious bleeding complications, which is similar to results from previous studies. This is important because it supports the use of Fortelyzin for patients suffering from strokes, potentially leading to better treatment options.
Who this helps: Patients with acute ischemic stroke and their healthcare providers.
[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].
2025
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more
Plain English This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues.
Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.
[Nonimmunogenic staphylokinase in the treatment of acute ischemic stroke (FRIDA trial results)].
2022
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Gusev EI, Martynov MY, Shamalov NA, Yarovaya EB, Semenov MP +36 more
Plain English This study compared two treatments for patients suffering from acute ischemic stroke: non-immunogenic staphylokinase (NS) and alteplase (A). Out of 336 patients, 50% of those who received NS had a good recovery after 90 days, while 41% of those who received alteplase did, showing that NS may be a more effective option. It also resulted in fewer serious complications, with 13% of NS patients experiencing significant side effects compared to 22% in the alteplase group.
Who this helps: This helps patients who are dealing with acute ischemic strokes.
Prognostic Value of Investigating Neuron-Specific Enolase in Patients with Ischemic Stroke.
2021
Sovremennye tekhnologii v meditsine
Kurakina АS, Semenova TN, Guzanova EV, Nesterova VN, Schelchkova NA +2 more
Plain English This study looked at how levels of a protein called neuron-specific enolase (NSE) in the blood can predict recovery outcomes for patients who have had an ischemic stroke. They found that when NSE levels are below 2 ng/ml within the first 48 hours after the stroke, there is a high chance of good recovery, with an odds ratio of 12.4, while levels above 2.6 ng/ml are linked to a higher risk of death. This is important because measuring NSE can help doctors identify which patients are likely to recover well and which may need more intensive care.
Who this helps: This research benefits patients who have suffered an ischemic stroke and their doctors.